论文部分内容阅读
对九株临床常见菌做了双氟沙星(Difloxacin)的小鼠体内保护试验。结果显示,口服双氟沙星对大肠杆菌、绿脓杆菌、肺炎克雷伯氏杆菌、肺炎链球菌和金葡球菌感染小鼠的保护作用明显优于氟哌酸(Norfloxacin)。口服双氟沙星对肺炎链球菌感染小鼠的保护作用比氟哌酸强6～20倍,对金葡球菌感染小鼠的保护作用比氟哌酸强13倍。用双氟沙星治疗肺炎克雷伯氏杆菌感染小鼠的半数保护剂量作用有效于氟哌酸(双氟沙星ED_(50)1.08mg/kg,氟哌酸ED_(50)4.39mg/kg),双氟沙星的保护作用是氟哌酸的4倍。双氟沙星对大肠杆菌引起的感染小鼠保护作用比氟哌酸保护作用至少强2～3倍。 研究结果表明,双氟沙星具有良好的体内抗菌作用。
Doxorubicin (Difloxacin) mice in vivo protection tests were performed on nine clinical common bacteria. The results showed that the oral protection of bifloxacin against E. coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Streptococcus pneumoniae and Staphylococcus aureus in mice significantly better than Norfloxacin. Oral administration of bivofloxacin against S. pneumoniae infected mice than norfloxacin strong 6 to 20-fold protection against Staphylococcus aureus infection in mice than norfloxacin 13 times stronger. The dose-effect of half-protective dose of bifloxacin in mice infected with Klebsiella pneumoniae was effective in treatment with norfloxacin (ED_ (50) 1.08mg / kg, norfloxacin ED_ (50) 4.39mg / kg ), The protective effect of bifloxacin is 4 times of norfloxacin. The protective effect of bifloxacin on E. coli-infected mice was at least 2-3 times stronger than that of norfloxacin. The results show that, ofloxacin has a good antibacterial effect in vivo.